Welcome to Valneva
A leading pure play vaccine company.
— January 5, 2017
Valneva Announces a New Research License Agreement with MSD Animal Health for the Development of Vaccines in the EB66® Cell LineRead more
— December 9, 2016
Valneva Receives FDA and European Approvals to Start Clinical Testing of Lyme Disease Vaccine Candidate
— Financial Calendar
February 23, 2017
Preliminary 2016 Results (Revenues, Cash) March 23, 2017
2016 Financial Statements
See all dates
Valneva's CEO Thomas Lingelbach
comments on Group Strategy
— Product pipeline
Our goal is to develop and launch a continuous flow of products. We strive for a balance between in-house development and strategic partnerships to accelerate vaccine development.
– Upcoming conferences and fairs
J.P. Morgan 35th Annual Healthcare Conference
San Francisco, US
January 9-12, 2017
Invest Securities BioMed Event
January 26, 2017
10th Kempen Life Sciences Conference
April 18-19, 2017
A leading pure play vaccine company with international footprint.